《Table 1 Clinical trials classified on molecular targets》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《Precision medicine in gastric cancer》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

Surgical resection with pre-and post-operative chemotherapy and/or radiotherapy is the primary curative treatment of early-stage GC with a 5-year survival of about30%[117-119].Systemic chemotherapy is used to treat patients with localized and advanced GC.Palliative systemic therapy and chemo/radiotherapy are standard treatment options for patients with unresectable or metastatic advanced GC.Neoadjuvant chemotherapy with surgery is associated with the improved survival of patients with metastatic disease[120].Perioperative chemotherapy with docetaxel，oxaliplatin，fluorouracil，and leucovorin（FLOT）significantly improves progressionfree survival（referred to herein as PFS）and OS among patients with resectable GC compared with epirubicin，cisplatin，and fluorouracil or capecitabine（ECF/ECX）[121].A Bayesian network meta-analysis obtained an estimate of the efficacy of perioperative FLOT and neoadjuvant treatments for resectable GC.Compared with surgery alone，perioperative cisplatin with fluorouracil（CF），perioperative ECF/ECX，and perioperative FLOT significantly improved survival.The most effective neoadjuvant treatment for the disease is likely to be perioperative FLOT[122].Targeted therapy，a new therapeutic strategy，may improve the survival of patients with advanced GC.Clinical trials with targeted therapies have been performed in patients with GC.Table 1 shows some clinical trials，completed or ongoing，classified by specific molecular target.